{"symbol":"AMGN","provider":"yahoo-finance","fetchedAt":"2025-12-23T08:21:36.221Z","asOfDate":"2025-12-23","articles":[{"id":"34a3a50e-f6af-3c87-bcd0-95f41ef39cc8","title":"Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know","url":"https://finance.yahoo.com/news/amgen-amgn-outpaces-stock-market-225001187.html","publisher":"Zacks","publishedAt":"2025-12-22T22:50:01.000Z","relatedTickers":["^DJI","^GSPC"],"mainIdea":"Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know","summary":"Zacks: Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know. The latest trading day saw Amgen (AMGN) settling at $331.39, representing a +1.22% change from its previous close. Related tickers mentioned: ^DJI, ^GSPC."},{"id":"65a995e2-731e-3bd8-ac46-a5c62b2ff7d7","title":"SCHD vs. NOBL: Different Paths to Dividend Stability","url":"https://finance.yahoo.com/m/65a995e2-731e-3bd8-ac46-a5c62b2ff7d7/schd-vs.-nobl%3A-different.html","publisher":"Motley Fool","publishedAt":"2025-12-22T21:31:52.000Z","relatedTickers":["SCHD"],"mainIdea":"SCHD vs. NOBL: Different Paths to Dividend Stability","summary":"Motley Fool: SCHD vs. NOBL: Different Paths to Dividend Stability. Both ETFs target dividend paying stocks, but their rules determine whether investors receive higher income or stricter dividend consistency Related tickers mentioned: SCHD."},{"id":"9ecc3ce3-9c26-3064-a686-e56ae6206c94","title":"Celldex Therapeutics Stock Gets RS Rating Lift","url":"https://finance.yahoo.com/m/9ecc3ce3-9c26-3064-a686-e56ae6206c94/celldex-therapeutics-stock.html","publisher":"Investor's Business Daily","publishedAt":"2025-12-22T20:42:10.000Z","relatedTickers":["CLDX"],"mainIdea":"Celldex Therapeutics Stock Gets RS Rating Lift","summary":"Investor's Business Daily: Celldex Therapeutics Stock Gets RS Rating Lift. A Relative Strength Rating upgrade for Celldex Therapeutics shows improving technical performance. Will it continue? Related tickers mentioned: CLDX."}]}
